Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
- 4 March 2013
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 33 (9) , 1158-1166
Abstract
Approximately 50% of melanomas depend on mutant B-RAF for proliferation, metastasis and survival. The inhibition of oncogenic B-RAF with highly targeted compounds has produced remarkable albeit short-lived clinical responses in B-RAF mutant melanoma patients. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to B-RAF inhibitors, and the identification of B-RAF targets may provide new strategies for managing melanoma. Oncogenic B-RAFV600E is known to promote the stabilizing phosphorylation of the anti-apoptotic protein Mcl-1, implicated in melanoma survival and chemoresistance. We now show that B-RAFV600E signaling also induces the transcription of Mcl-1 in melanocytes and melanoma. We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAFV600E activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation. Consequently, suppression of STAT3 activity disrupted B-RAFV600E-mediated induction of Mcl-1 and reduced melanoma cell survival. We propose that STAT3 has a central role in the survival and contributes to chemoresistance of B-RAFV600E melanoma.Keywords
This publication has 50 references indexed in Scilit:
- Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimSCell Death & Disease, 2010
- BRAF as therapeutic target in melanomaBiochemical Pharmacology, 2010
- B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant MelanomaCurrent Oncology Reports, 2010
- Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.Oncology Reports, 2008
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1Clinical Cancer Research, 2007
- Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanomaLaboratory Investigation, 2007
- Cutaneous Malignant MelanomaMayo Clinic Proceedings, 2006
- Nuclear expression of the antiapoptotic protein survivin in malignant melanomaCancer, 2006
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001